Extracorporeal Photochemotherapy (Photopheresis)

Extracorporeal photochemotherapy (ECP/photopheresis) is covered for erythrodermic cutaneous T‑cell lymphoma (mycosis fungoides/Sezary), refractory acute cardiac allograft rejection, refractory lung transplant bronchiolitis obliterans, as last‑resort for other solid‑organ transplant rejection, and for refractory graft‑versus‑host disease after allogeneic stem‑cell transplant, provided patients are resistant/dependent on high‑dose steroids and refractory to ≥2 specified immunosuppressive agents (or ECP is used only after standard therapies have failed). ECP is excluded/considered experimental or not covered for many other indications (e.g., atopic dermatitis, autoimmune diseases, BOS after allogeneic SCT, kidney transplant rejection, systemic sclerosis, multiple sclerosis, type 1 diabetes) and numerous listed ICD‑10 codes (J42 is covered only for lung transplant rejection, not BOS after allogeneic SCT).

"Morphea (localized scleroderma)"